With the idea that tau which represents the other relevant key player in the onset and progression of AD, other than Aβ might be a druggable target of the peptide activity we evaluated the potential protective effects of Aβ1-6A2V(D) against the toxicity of the tau protein. The gene discussed is MAPT; the disease is Alzheimer disease.